Effects of rotigotine on sleep in Parkinson’s disease patients: a Parkinson’s KinetiGraph study

IntroductionRecent studies suggest that the dopamine agonist (DA) rotigotine improves sleep among Parkinson disease (PD) patients. Parkinson’s KinetiGraph (PKG) offers a home-based alternative for evaluating sleep. We investigated the effect of rotigotine on sleep in PD patients with PKG and questio...

Full description

Saved in:
Bibliographic Details
Main Authors: Sotirios Grigoriou, Carin Janz, Malcolm Horne, Filip Bergquist, Nil Dizdar, Per Odin
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Neurology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fneur.2025.1591537/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849327111988314112
author Sotirios Grigoriou
Sotirios Grigoriou
Carin Janz
Carin Janz
Malcolm Horne
Filip Bergquist
Filip Bergquist
Nil Dizdar
Per Odin
Per Odin
author_facet Sotirios Grigoriou
Sotirios Grigoriou
Carin Janz
Carin Janz
Malcolm Horne
Filip Bergquist
Filip Bergquist
Nil Dizdar
Per Odin
Per Odin
author_sort Sotirios Grigoriou
collection DOAJ
description IntroductionRecent studies suggest that the dopamine agonist (DA) rotigotine improves sleep among Parkinson disease (PD) patients. Parkinson’s KinetiGraph (PKG) offers a home-based alternative for evaluating sleep. We investigated the effect of rotigotine on sleep in PD patients with PKG and questionnaires. Secondarily, the effects of rotigotine on daytime sleepiness, motor symptoms, quality of life and correlations between PKG variables and rating scale results were investigated.MethodThirty-two PD patients with sleep disturbances (Clinical Global Impression-Severity (CGI-S) ≥ 3) were included in this observational study. Before start of treatment and during stable dose with rotigotine patients were assessed with Parkinson’s disease sleep scale 2 (PDSS-2), Epworth Sleepiness Scale (ESS), Parkinson’s disease quality of life questionnaire (PDQ-8), European Quality of life five dimensions (EQ-5D-5L) questionnaires and PKG recordings (24 h/day for 6 days). Clinicians evaluated sleep using CGI scales, and PD severity using Clinical Impression of Severity Index for Parkinson’s Disease (CISI-PD).ResultsRotigotine did not significantly improve total PDSS-2 or PKG nighttime scores in the entire group, but PDSS-2 improved among patients with PDSS-2 ≥ 18 at baseline and for DA-naïve patients (p = 0.009 and p = 0.013). Treatment improved percent time tremor (PTT; p < 0.001), percent time immobile during daytime (PTID; p < 0.001), CISI-PD (p < 0.001), PDQ-8 (p = 0.014), and EQ-5D-5L (p = 0.002). No significant correlations were found between PTID and ESS-total (ρ = −0.046, p = 0.718) or between combined sleep score (CSS) and PDSS-2 total (ρ = −0.065, p = 0.612).ConclusionRotigotine improved sleep in patients with a baseline PDSS-2 ≥ 18 and in DA-naïve patients, but not in the whole study group. Additionally, rotigotine seemed to improve motor function and quality of life. PTID improved with treatment. Whether the improved PTID reflects a positive impact on daytime sleepiness or just improved mobility and to what extent PKG nighttime scores accurately represent sleep variables remains to be investigated in further studies.
format Article
id doaj-art-9c7b52c15a734f0fa3ece75a6fdea2af
institution Kabale University
issn 1664-2295
language English
publishDate 2025-05-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Neurology
spelling doaj-art-9c7b52c15a734f0fa3ece75a6fdea2af2025-08-20T03:47:58ZengFrontiers Media S.A.Frontiers in Neurology1664-22952025-05-011610.3389/fneur.2025.15915371591537Effects of rotigotine on sleep in Parkinson’s disease patients: a Parkinson’s KinetiGraph studySotirios Grigoriou0Sotirios Grigoriou1Carin Janz2Carin Janz3Malcolm Horne4Filip Bergquist5Filip Bergquist6Nil Dizdar7Per Odin8Per Odin9Division of Neurology, Department of Clinical Sciences Lund, Lund University, Lund, SwedenDepartment of Neurology, Rehabilitation Medicine, Memory and Geriatrics, Skane University Hospital, Lund, SwedenDivision of Neurology, Department of Clinical Sciences Lund, Lund University, Lund, SwedenDepartment of Neurology, Rehabilitation Medicine, Memory and Geriatrics, Skane University Hospital, Lund, SwedenDepartment of Medicine, St Vincent’s Hospital, University of Melbourne, Melbourne, VIC, AustraliaDivision of Neurology, Sahlgrenska University Hospital, Gothenburg, SwedenDepartment of Pharmacology, University of Gothenburg, Gothenburg, SwedenDepartment of Biomedical and Clinical Sciences, Linkoping University, Linköping, SwedenDivision of Neurology, Department of Clinical Sciences Lund, Lund University, Lund, SwedenDepartment of Neurology, Rehabilitation Medicine, Memory and Geriatrics, Skane University Hospital, Lund, SwedenIntroductionRecent studies suggest that the dopamine agonist (DA) rotigotine improves sleep among Parkinson disease (PD) patients. Parkinson’s KinetiGraph (PKG) offers a home-based alternative for evaluating sleep. We investigated the effect of rotigotine on sleep in PD patients with PKG and questionnaires. Secondarily, the effects of rotigotine on daytime sleepiness, motor symptoms, quality of life and correlations between PKG variables and rating scale results were investigated.MethodThirty-two PD patients with sleep disturbances (Clinical Global Impression-Severity (CGI-S) ≥ 3) were included in this observational study. Before start of treatment and during stable dose with rotigotine patients were assessed with Parkinson’s disease sleep scale 2 (PDSS-2), Epworth Sleepiness Scale (ESS), Parkinson’s disease quality of life questionnaire (PDQ-8), European Quality of life five dimensions (EQ-5D-5L) questionnaires and PKG recordings (24 h/day for 6 days). Clinicians evaluated sleep using CGI scales, and PD severity using Clinical Impression of Severity Index for Parkinson’s Disease (CISI-PD).ResultsRotigotine did not significantly improve total PDSS-2 or PKG nighttime scores in the entire group, but PDSS-2 improved among patients with PDSS-2 ≥ 18 at baseline and for DA-naïve patients (p = 0.009 and p = 0.013). Treatment improved percent time tremor (PTT; p < 0.001), percent time immobile during daytime (PTID; p < 0.001), CISI-PD (p < 0.001), PDQ-8 (p = 0.014), and EQ-5D-5L (p = 0.002). No significant correlations were found between PTID and ESS-total (ρ = −0.046, p = 0.718) or between combined sleep score (CSS) and PDSS-2 total (ρ = −0.065, p = 0.612).ConclusionRotigotine improved sleep in patients with a baseline PDSS-2 ≥ 18 and in DA-naïve patients, but not in the whole study group. Additionally, rotigotine seemed to improve motor function and quality of life. PTID improved with treatment. Whether the improved PTID reflects a positive impact on daytime sleepiness or just improved mobility and to what extent PKG nighttime scores accurately represent sleep variables remains to be investigated in further studies.https://www.frontiersin.org/articles/10.3389/fneur.2025.1591537/fullParkinson’s diseaseParkinson’s KinetiGraphrotigotinesleep disturbancesParkinson disease sleep scale-2sleep quality
spellingShingle Sotirios Grigoriou
Sotirios Grigoriou
Carin Janz
Carin Janz
Malcolm Horne
Filip Bergquist
Filip Bergquist
Nil Dizdar
Per Odin
Per Odin
Effects of rotigotine on sleep in Parkinson’s disease patients: a Parkinson’s KinetiGraph study
Frontiers in Neurology
Parkinson’s disease
Parkinson’s KinetiGraph
rotigotine
sleep disturbances
Parkinson disease sleep scale-2
sleep quality
title Effects of rotigotine on sleep in Parkinson’s disease patients: a Parkinson’s KinetiGraph study
title_full Effects of rotigotine on sleep in Parkinson’s disease patients: a Parkinson’s KinetiGraph study
title_fullStr Effects of rotigotine on sleep in Parkinson’s disease patients: a Parkinson’s KinetiGraph study
title_full_unstemmed Effects of rotigotine on sleep in Parkinson’s disease patients: a Parkinson’s KinetiGraph study
title_short Effects of rotigotine on sleep in Parkinson’s disease patients: a Parkinson’s KinetiGraph study
title_sort effects of rotigotine on sleep in parkinson s disease patients a parkinson s kinetigraph study
topic Parkinson’s disease
Parkinson’s KinetiGraph
rotigotine
sleep disturbances
Parkinson disease sleep scale-2
sleep quality
url https://www.frontiersin.org/articles/10.3389/fneur.2025.1591537/full
work_keys_str_mv AT sotiriosgrigoriou effectsofrotigotineonsleepinparkinsonsdiseasepatientsaparkinsonskinetigraphstudy
AT sotiriosgrigoriou effectsofrotigotineonsleepinparkinsonsdiseasepatientsaparkinsonskinetigraphstudy
AT carinjanz effectsofrotigotineonsleepinparkinsonsdiseasepatientsaparkinsonskinetigraphstudy
AT carinjanz effectsofrotigotineonsleepinparkinsonsdiseasepatientsaparkinsonskinetigraphstudy
AT malcolmhorne effectsofrotigotineonsleepinparkinsonsdiseasepatientsaparkinsonskinetigraphstudy
AT filipbergquist effectsofrotigotineonsleepinparkinsonsdiseasepatientsaparkinsonskinetigraphstudy
AT filipbergquist effectsofrotigotineonsleepinparkinsonsdiseasepatientsaparkinsonskinetigraphstudy
AT nildizdar effectsofrotigotineonsleepinparkinsonsdiseasepatientsaparkinsonskinetigraphstudy
AT perodin effectsofrotigotineonsleepinparkinsonsdiseasepatientsaparkinsonskinetigraphstudy
AT perodin effectsofrotigotineonsleepinparkinsonsdiseasepatientsaparkinsonskinetigraphstudy